Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin

NCT00162812 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
338
Enrollment
OTHER
Sponsor class

Stopped Low accrual rate

Conditions

Interventions

Sponsor

Jules Bordet Institute

Collaborators